As the life science industry continues to advance the discovery and development of new therapies and cures, research-based companies are faced with tackling even more complex and difficult-to-treat diseases. As part of their efforts, companies are beginning to recognize the value of bringing together researchers, Patients, caregivers and advocacy groups in a unified and comprehensive way to meet a common goal.
Developing these relationships among all these parties is vital for advancing drug discovery and development–Because Patients Can’t Wait®. And that’s why we are so pleased to present this white paper–Patient Advocacy: An Emerging Role Within Pharma and Biotechnology. The white paper is based on a survey that was conducted by Merrill DataSite in June of 2012 and the BioNJ webinar Helping Companies Achieve a High Return on Investment in Patient Advocacy Programs held on December 19, 2012.
We hope you find this white paper to be beneficial as you look to grow your patient advocacy function and ensure that the voice of the Patient is heard.